Exercise and Metformin in Colorectal and Breast Cancer Survivors
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Metformin is a medication that is commonly used in the treatment of diabetes. Recently small studies in cancer patients without diabetes suggest that metformin may benefit in lowering insulin levels. In those studies of patients with cancer but not diabetes, glucose (or sugar) levels in the blood are generally no lowered. Insulin and insulin-like growth factors affect the growth of cancer cells.
This randomized study will compare different interventions; exercise, exercise and metformin, metformin alone, or a control arm. The investigators are not directly testing how either exercise or metformin affects your disease. The investigators are testing how they affect insulin levels in your body as well as other blood markers. The investigators believe that these blood tests may either be related to cancer recurrences or be an early sign of cancer recurrences and they are testing how both exercise and metformin may change those markers.
| Condition | Intervention | Phase |
|---|---|---|
|
Colorectal Cancer Breast Cancer |
Behavioral: Exercise training Drug: Exercise training plus metformin Drug: Metformin Other: Educational information |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | Randomized Phase II Study of Exercise and Metformin in Colorectal and Breast Cancer Survivors |
- Determine whether supervised exercise training alone and metformin, either alone or in combination can decrease fasting insulin level from baseline to 3 months in patients who completed standard therapy for stage I-III colorectal or breast cancer. [ Time Frame: 3 years ] [ Designated as safety issue: No ]Fasting insulin levels in blood will be drawn at baseline, 3 months and 6 months
- Compare changes in other insulin-related biomarkers [ Time Frame: 3 years ] [ Designated as safety issue: No ]Markers related to insulin and insulin-like growth factors (including C peptide, insulin-like growth factor 1 [IGF-1], IGF binding protein-3 [IGFBP-3], adiponectin, lectin) will be measured by a blood draw at baseline, 3 months and 6 months
- Explore for an interaction effect in addition to an additive effect of exercise and metformin in reducing fasting insulin level over the 3 month intervention [ Time Frame: 3 years ] [ Designated as safety issue: No ]
- Compare changes in body composition by treatment arm [ Time Frame: 3 years ] [ Designated as safety issue: No ]Measures will include body mass index (BMI) at baseline and 3 months
- Compare change in pro-inflammatory markers potentially related to insulin resistance by treatment arm [ Time Frame: 3 years ] [ Designated as safety issue: No ]Inflammatory markers measured in blood at baseline, 3 months and 6 months
- Compare self-directed change in diet quality by treatment arm [ Time Frame: 3 years ] [ Designated as safety issue: No ]Participants will complete a food frequency questionnaire at baseline and 3 months
| Estimated Enrollment: | 200 |
| Study Start Date: | May 2011 |
| Estimated Primary Completion Date: | May 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Exercise training
Exercise training with exercise physiologist
|
Behavioral: Exercise training
Two supervised exercise sessions per week
|
|
Active Comparator: Exercise training with metformin
Exercise training with exercise physiologist with oral metformin
|
Drug: Exercise training plus metformin
Two supervised exercise sessions per week. Oral metformin QD for 2 weeks, then BID
|
|
Active Comparator: Metformin
Metformin
|
Drug: Metformin
Oral metformin QD for two weeks, then BID
|
|
Active Comparator: Control
Educational information
|
Other: Educational information
educational information
|
Detailed Description:
Subjects will be randomized into one of four groups: exercise training, exercise training and metformin, metformin alone, or control arm. All subjects will have lifestyle measurements, interviews regarding activity level, diet questionnaires, and blood tests.
Subjects randomized to exercise training will participate in two supervised exercise sessions per week with an exercise physiologist for 3 months. They will also be asked to exercise on their own for up to an additional 120 minutes each week.
Subjects randomized to exercise training and metformin will participate in two supervised exercise sessions per week and will take metformin. Metformin will be taken once daily for the first two weeks and then twice daily for 3 months.
Subjects randomized to metformin will take metformin once daily for the first two weeks and then twice daily.
Subjects on the control arm will receive a packet of educational information on nutrition and physical activity developed by the National Cancer Institute and American Cancer Society. In addition to education information, they will be offered two supervised sessions with an exercise physiologist as well as a pedometer 3 months after enrollment in the study.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically confirmed stage I-III colorectal or breast cancer
- Undergone curative-intent complete surgical resection and completed all adjuvant therapy (if indicated) at least 2 months prior to enrollment
- Note: Breast cancer subjects on hormonal therapy or trastuzumab only therapy and colorectal cancer subjects on adjunctive therapies not considered cytotoxic chemotherapy (including those participating in CALGB 80702 receiving only celocoxib/placebo) are eligible.
- Participants will be allowed to receive concomitant adjuvant endocrine therapy for breast cancer; however, all endocrine agents must be initiated at least 1 month prior to enrollment in the study and continued throughout the duration of study participation.
- Less than 120 minutes of exercise per week
- Approval by oncologist or surgeon
- English speaking and able to read English
- No planned surgery anticipated in the 3 month intervention period
- At least one month from any major surgery to start of intervention including colostomy reversal
Exclusion Criteria:
- Concurrent other malignancy or history of other malignancy treated within the past 3 years (other than non-melanoma skin cancer or in-situ cervical cancer)
- Metastatic disease
- Scheduled to receive any form of further adjuvant cancer therapy
- Currently on medication for diabetes treatment
- Pregnant or breast-feeding
- Any condition associated with increased risk of metformin-associated lactic acidosis (prior renal failure or liver failure, history of acidosis of any type; habitual intake of 3 or more alcoholic beverages per day)
- Known hypersensitivity or intolerance to metformin
Contacts and Locations| Contact: Jeffrey Meyerhardt, MD, MPH | 617-632-6855 | jeffrey_meyerhardt@dfci.harvard.edu |
| United States, Massachusetts | |
| Dana-Farber Cancer Institute | Recruiting |
| Boston, Massachusetts, United States, 02215 | |
| Principal Investigator: Jeffrey Meyerhardt, MD, MPH | |
| United States, North Carolina | |
| Duke University | Recruiting |
| Durham, North Carolina, United States, 27710 | |
| Principal Investigator: Lee Jones, PhD | |
| Principal Investigator: | Jeffrey Meyerhardt, MD, MPH | Dana-Farber Cancer Institute |
More Information
No publications provided
| Responsible Party: | Jeffrey A. Meyerhardt, MD, Principal Investigator, Dana-Farber Cancer Institute |
| ClinicalTrials.gov Identifier: | NCT01340300 History of Changes |
| Other Study ID Numbers: | 11-009 |
| Study First Received: | April 7, 2011 |
| Last Updated: | April 30, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Dana-Farber Cancer Institute:
|
Colorectal Breast Insulin Exercise |
Additional relevant MeSH terms:
|
Breast Neoplasms Colorectal Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms |
Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Metformin Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 22, 2013